2026-10-25
Hawkins, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,944 +1.18%
S&P 7,385 +0.42%
GOLD $4,067 −1.12%
BTC $75,586 −0.47%
VIX 25.28 −10.29%
latest tape · as of 18:01 UTC
The Screen · Basic Materials · Specialty Chemicals
Hawkins, Inc.
HWKN · Nasdaq · USD · Market cap $3.2B · 1,200 employees
Hawkins, Inc.
Not yet scored152.00 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 18:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price152.00 USD at the 5 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 5 Nov 2026
- Our regime readMarkup, as of 5 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans to puts (put/call 1.00)
- Last reviewed5 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $108.53 to $124.81, base estimate $108.53 (screen dated 2026-11-05).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.00, read 2026-11-05
- Ethical screen not yet scored
Price152.00 USD
Fair value108.53
Ethical score98.9/100
Value readOvervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-11-02Read Markup152.53-0.3% to today Accumulation gives way to Markup after a 23% rise in 4 weeks
2026-10-02Read Accumulation123.99+22.6% to today ✓Markdown gives way to Accumulation with volume flow in agreement
2026-09-01Read Markdown124.80+21.8% to today Distribution gives way to Markdown after a 14% slide in 4 weeks
2026-08-01Read Distribution144.41+5.3% to today Markdown gives way to Distribution after a 7% slide in 4 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markup label.
Hawkins, Inc. holds its Markup at $152.00. Consolidating, no directional conviction, held for 3 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 3 days |
| Price at the screen | $152.00 |
| Valuation | 38.85 trailing · 32.87 forward price to earnings |
| Values screen | Not scored · score 98.9 |
| Beta | 0.74 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 2.79% | Below 33% | Interest-bearing debt is just 2.8% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.17% | Below 33% | Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Hawkins, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Hawkins, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 3%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 5 Nov 2026: it trades above our $108.53 fair value estimate, moderate competitive moat, 7.60% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 40.1% above the base estimate.
Third-party analyst targets: 4 covering, consensus Buy. The average target sits +17% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $108.53, with a range of $108.53 to $124.81, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it gives us pause
At 32.9x forward earnings, the price already runs ahead of the business. It trades 44% above our $108.53 fair value, so you would be buying at a premium, not a discount. The moderate moat is real, but quality alone does not make an expensive price cheap.
| Forward P/E | 32.9xexpensive even after accounting for its growth |
| Trailing P/E | 38.9xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 3.96 |
| EPS, forward | 4.68 |
| Revenue growth | +7.6%slow but positive growth |
| Profit margin | 7.3%thin but positive margins |
| Return on equity | 15.6%a solid return on shareholder capital |
| FCF yield | 2.53% |
| Dividend yield | 0.48% |
| Debt to equity | 0.47minimal debt: a conservative balance sheet |
| Current ratio | 2.27comfortably covers its short-term bills |
| Beta | 0.74steadier than the market |
| Short interest, float | 0.08% |
| 52-week range | 116.05 - 174.12 |
| Moat | MODERATE |
| Market cap | $3.2B |
| Employees | 1,200 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeHWKN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-02
Markup · changed $152.53
+15.7% Entry 16
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. Since the last review it its composite score eased.
2026-10-26
Accumulation $131.82
+0.0% Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Accumulation $131.82
+0.0% Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24
Accumulation $131.82
+0.0% Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23
Accumulation $131.82
+0.0% Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22
Accumulation $131.82
+0.0% Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21
Accumulation $131.82
+0.0% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20
Accumulation $131.82
+0.0% Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19
Accumulation $131.82
-0.1% Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.1% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14
Accumulation $131.89
+6.4% Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.4% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 13%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (3 analysts) rates it buy, with a mean price target of $189.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Can Hawkins (HWKN) Stock Sustain Its Q2 Earnings Rally? Yahoo Finance · 9d ago
- Hawkins (HWKN) Stock Looks Fully Priced On Current Cash Flow Yahoo Finance · 10d ago
- Why Hawkins Stock Crushed the Market on Tuesday Yahoo Finance · 10d ago
- Hawkins (NASDAQ:HWKN) Shares Rise 8% After Q2 Earnings Exceed Estimates and Revenue Reaches $313.8 Million Yahoo Finance · 10d ago
- Hawkins soars 12% on strong second quarter earnings beat Yahoo Finance · 11d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
FULH.B. Fuller Company
KWRQuaker Chemical Corporation
WDFCWD-40 Company
IOSPInnospec Inc.
NGVTIngevity Corporation
ASHAshland Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-13 | MANGINE DAVID J. | Officer | 1,906 | · | |
| 2026-05-13 | JONES GREGORY ALAN | Officer | 1,970 | · | |
| 2026-05-13 | HAWKINS PATRICK H | Chief Executive Officer | 16,934 | · | |
| 2026-05-13 | OLDENKAMP JEFFREY PAUL | Chief Financial Officer | 8,435 | · | |
| 2026-05-13 | GRAHEK DREW M | Officer | 2,697 | · | |
| 2026-05-13 | ROZEBOOM SHIRLEY A. | Officer | 1,906 | · | |
| 2026-05-13 | LANGE DOUGLAS A. | Officer | 1,994 | · | |
| 2026-02-23 | HAWKINS PATRICK H | Chief Executive Officer | 1,040 | · | |
| 2026-02-05 | FAULCONBRIDGE JAMES A | Director | 3,000 | $388,860 | |
| 2025-12-09 | GRAHEK DREW M | Officer | 1,460 | $184,460 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $171.48 | -10.9% | $0.19 | $892 | -10.8% |
| 2 months | $147.92 | +3.3% | $0.19 | $1,034 | +3.4% |
| 3 months | $139.54 | +9.5% | $0.19 | $1,097 | +9.7% |
| 6 months | $140.98 | +8.4% | $0.38 | $1,087 | +8.7% |
| 1 year | $135.19 | +13.1% | $0.76 | $1,136 | +13.6% |
| 2 years | $86.57 | +76.5% | $1.48 | $1,782 | +78.2% |
| 3 years | $49.94 | +206.0% | $2.12 | $3,103 | +210.3% |
| 5 years | $31.53 | +384.7% | $3.24 | $4,950 | +395.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever HWKN does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.